Leonard Frank X - Jan 4, 2024 Form 3 Insider Report for NovoCure Ltd (NVCR)

Role
EVP, Pres., Novocure Oncology
Signature
Steven Robbins, as attorney in fact for Leonard, Frank X.
Stock symbol
NVCR
Transactions as of
Jan 4, 2024
Transactions value $
$0
Form type
3
Date filed
1/12/2024, 04:57 PM
Previous filing
Mar 7, 2023
Next filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NVCR Ordinary Shares 45.3K Jan 4, 2024 Direct
holding NVCR Restricted Share Units 5.79K Jan 4, 2024 Direct F1
holding NVCR Restricted Share Units 2.9K Jan 4, 2024 Direct F2
holding NVCR Restricted Share Units 2.28K Jan 4, 2024 Direct F3
holding NVCR Restricted Share Units 6.21K Jan 4, 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 16K $153.09 Direct F5
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 11.3K $84.68 Direct F6
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 7.81K $83.30 Direct F7
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 4.93K $80.59 Direct F8
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 30.4K $80.59 Direct F9
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 31K $76.97 Direct F10
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 11.6K $73.20 Direct F11
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 1.44K $69.37 Direct F12
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 8.98K $69.37 Direct F12
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 14.6K $47.04 Direct F7
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 16.1K $34.00 Direct F7
holding NVCR Stock Options (Right to buy) Jan 4, 2024 Ordinary Shares 10.5K $21.15 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units that are scheduled to vest in equal installments on March 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F10 Options to buy 30,971 ordinary shares will vest in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F11 Options to buy 11,609 ordinary shares, 2,903 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F12 Options to buy 10,422 ordinary shares, 7,817 shares of which are currently exercisable and the remainder will vest on March 2, 2024, subject to the reporting person's continued employment through such date.
F2 Represents restricted share units that are scheduled to vest on March 2, 2024, subject to the reporting person's continued employment through such date.
F3 Represents restricted share units that are scheduled to vest in equal installments on November 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F4 Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F5 Options to buy 16,003 ordinary shares, 8,002 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F6 Options to buy 11,336 ordinary shares, 8,502 shares of which are currently exercisable and the remainder will vest on September 1, 2024, subject to the reporting person's continued employment through such date.
F7 Currently exercisable.
F8 Options to buy 4,933 ordinary shares, 2,467 shares of which are currently exercisable and the remainder will vest on March 1, 2024, subject to the reporting person's continued employment through such date.
F9 Options to buy 30,422 ordinary shares, 7,606 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.